The nation of Zimbabwe has rejected a major US healthcare agreement worth $367m (272 million pounds) over five years over Washington's request for confidential information.
This move was revealed following a internal memorandum from December was leaked, indicating that President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
An official representative later stated that the US was demanding access to biological samples for research and profit while refused to share the benefits from future treatments.
"We are forced to start the difficult and regrettable task of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for further dialogue to secure a deal acceptable to both sides so the nation's critical HIV treatment initiative can be sustained.
Wider Implications
This rejection comes after a similar situation in Kenya, where a court halted a related health funding agreement after concerns were filed about the security of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump argued its expenditure was "wasteful" and his administration was seeking government-to-government deals to boost openness and accountability.
Based on reports, Sixteen African countries have so far agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration could have provided immense benefits for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy via US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," Mangwana explained.
"Effectively, our country would provide the basic resources for scientific discovery with no certainty that the end products would be accessible to our people should a future pandemic arise."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting frameworks already established through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This mechanism is intended to guarantee that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how subsequent co-operation could be arranged in a manner that honours the independence and dignity of each country."
Medical Community Response
A leading public health body stated it acknowledged the government's concerns, but urged that negotiations must proceed given that a large portion of the nation's HIV programmes depended on external financing.
"If specific concerns exist, including those relating to information security or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it added.
This impasse highlights the continuing debate between accepting crucial foreign assistance and protecting a country's data in an ever more data-driven world.